[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,590
  • Shares Outstanding, K 2,333
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,880 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-4.50
  • Growth Rate Est. (year over year) +22,300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +5.83%
on 06/29/26
1.3700 -20.43%
on 06/12/26
-0.2899 (-21.01%)
since 06/05/26
3-Month
1.0300 +5.83%
on 06/29/26
7.4900 -85.45%
on 04/07/26
-5.5199 (-83.51%)
since 04/06/26
52-Week
1.0300 +5.83%
on 06/29/26
85.8000 -98.73%
on 07/10/25
-29.0599 (-96.38%)
since 07/03/25

Most Recent Stories

More News
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

SOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL),  a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29,...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

SOLANA BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments...

ARTL : 1.0850 (-2.25%)
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Demonstrates ART26.12’s Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common...

ARTL : 1.0850 (-2.25%)
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate...

ARTL : 1.0850 (-2.25%)

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 1.1767
2nd Resistance Point 1.1433
1st Resistance Point 1.1267
Last Price 1.0850
1st Support Level 1.0767
2nd Support Level 1.0433
3rd Support Level 1.0267

See More

52-Week High 85.8000
Fibonacci 61.8% 53.4179
Fibonacci 50% 43.4150
Fibonacci 38.2% 33.4121
Last Price 1.0850
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.